Development Pipeline

BioAlliance is developing several programs in late- and early-stage clinical development, that leverage its Lauriad® and Transdrug® Drug Delivery platforms focused on overcoming drug resistance and the treatment of diseases where there is an unmet medical need. In addition, through alliances with leading French research institutes, the Company has developed a portfolio of new entities that are in early-stage development and address the oncology and HIV markets.

The following chart sets forth the Company's current portfolio and clinical progress:

Three products in Phase III, an advanced stage of development: miconazole Lauriad® (Loramyc®), doxorubicin Transdrug® and acyclovir Lauriad®